⌕
Rhythm Pharmaceuticals · RYTM · Nasdaq
Tenet 36 · Weak
Compare
$116.61+8.49%At closeTenet 36 · Weak
$116.61+9.13 (+8.49%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Rhythm Pharmaceuticals (RYTM) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (20 new · 44 increased · 20 reduced · 8 closed · 18 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 110 filers, Sep 30, 2026
# 13F FUNDS
110
13F VALUE
$453.7M
4.8M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 14, 2026Meeker David PPresident and CEOAcquired · Option exercise50,000$6.05↗
Sep 14, 2026Meeker David PPresident and CEODisposed · Open-market sale6,439$101.75↗
Sep 14, 2026Meeker David PPresident and CEODisposed · Open-market sale30,746$102.35↗
Sep 14, 2026Meeker David PPresident and CEODisposed · Open-market sale8,698$103.43↗
Sep 14, 2026Meeker David PPresident and CEODisposed · Open-market sale1,817$104.55↗
Sep 14, 2026Meeker David PPresident and CEODisposed · Open-market sale2,300$105.19↗
Sep 14, 2026Meeker David PPresident and CEODisposed · Option exercise50,000Employee Stock Option (Right to Buy)—↗
Aug 31, 2026Smith Hunter CChief Financial OfficerAcquired · Option exercise57,187$25.79↗
Aug 31, 2026Smith Hunter CChief Financial OfficerDisposed · Open-market sale23,072$104.59↗
Aug 31, 2026Smith Hunter CChief Financial OfficerDisposed · Open-market sale11,514$105.37↗
Aug 31, 2026Smith Hunter CChief Financial OfficerDisposed · Open-market sale28,188$106.20↗
Aug 31, 2026Smith Hunter CChief Financial OfficerDisposed · Option exercise57,187Employee Stock Option (Right to Buy)—↗
Aug 17, 2026Joshi ManherChief Medical OfficerAcquired · Grant / award50,000Stock Options (Right to Buy)—↗
Aug 17, 2026Joshi ManherChief Medical OfficerAcquired · Grant / award25,000Restricted Stock Units—↗
Aug 13, 2026Shulman JosephChief Technical OfficerAcquired · Option exercise2,024$6.80↗
Aug 13, 2026Shulman JosephChief Technical OfficerDisposed · Open-market sale5,079$119.75↗
Aug 13, 2026Shulman JosephChief Technical OfficerDisposed · Option exercise2,024Stock Options (Right to Buy)—↗
Aug 13, 2026Garfield AlastairChief Scientific OfficerDisposed · Open-market sale2,007$116.11↗
Aug 13, 2026Garfield AlastairChief Scientific OfficerDisposed · Open-market sale1,556$117.08↗
Aug 13, 2026Garfield AlastairChief Scientific OfficerDisposed · Open-market sale3,400$118.28↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals was held by 110 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.